In the recent future, multiple sclerosis might be obliterated, thanks to the integration of stem cell transplants in the search for therapy. Multiple sclerosis (MS) is a condition that has been giving scientists sleepless nights, due to its adverse nature. The disease interferes with the immune system, causing it to attack the nervous system. This results in impairments, as the nervous system runs some of the essential parts of the human body.
According to research conducted by the National Institute of Health, autologous stem cell implants resulted in the diminution of MS symptoms over time. The remedy is known as high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT). It involves the extraction of a patient’s stem cells, administering the dose, and then re-implanting the stem cells to rejuvenate the damaged tissues.
The new medication recorded astounding results, with nearly 70% of the volunteers reporting no new cases of MS symptoms, relapse or brain abrasions. The participants were evaluated five years after first receiving the treatment. This outcome was very promising, given that it was the first time the drug was tried out. Though the trials are still at preliminary stages, HDIT/HCT has already proven its superiority over its peers, especially if it is administered alone. The successful test of this remedy also offers a glimmer of hope to patients who are irresponsive to other medications.
About Shiva Gopal Vasishta
An affluent neurologist and psychologist, Dr. Shiva Gopal Vasishta is based in New Jersey at the hospital of Kennedy University. He attained his medical edification from the Nagpur Medical College in his native country, India. Shiva Gopal Vasishta later pursued a further medical education at the Boston County Hospital.
Owing to over four decades of extensive experience in the healthcare sector, Shiva Gopal Vasishta is a respected figure in the industry. Shiva is accredited by the national board of neurologists.